59839-23-5

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR
• Synonyms: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR;1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HYDROBROMIDE;1,2,3,4-Tetrahydroisoquinolin-6-olhydrobrimide;l,2,3,4-Tetrahydro-6-isoquinolinol Hydrobromide;1,2,3,4-Tetrahydro iso-6-hydroxy-quinoline HBr;1,2,3,4-Tetrahydro-iso-6-hydroxy-quinoline HBr;6-HYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE HBR;1,2,3,4-tetrahydro-6-hydroxy-isoquinoline-hydrobroMide
• CAS NO: 59839-23-5
• Molecular Formula: BrH*C₉H₁₁NO
• Molecular Weight: 230.10168
• Product Categories: Quinoline&Isoquinoline
• Mol File: 59839-23-5.mol
• Article Data: 19

Chemical Properties

• Melting Point: 196.7-197.8℃
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR(59839-23-5)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR(59839-23-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 59839-23-5(Hazardous Substances Data)

Usage

Uses

1,2,3,4-Tetrahydro-6-isoquinolin-6-ol Hydrobromide is a chemical reagent used in the organic synthesis. Used in the preparation of androgen receptor modulators (SARMs) as well as steroidmimetic and chimeric microtubule disruptors.

InChI:InChI=1/C9H11NO.BrH/c11-9-2-1-8-6-10-4-3-7(8)5-9;/h1-2,5,10-11H,3-4,6H2;1H

Upstream product

• 42923-77-3 6-methoxy-1,2,3,4-tetrahydro-isoquinoline 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 942150-85-8 bis(6-methoxy-N-1,2,3,4-tetrahydroisoquinolinyl)methane 
• 3179-09-7 1-methoxy-3-(2-nitrovinyl)benzene 
• 591-31-1 3-methoxy-benzaldehyde 
• 57196-62-0 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 860436-57-3 tert-butyl 6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 94085-74-2 6-hydroxy-2-(3-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 185057-06-1 6-Hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1429253-97-3 C₂₈H₂₆N₄O₂ 
• 1429254-04-5 C₂₄H₂₅N₃O₃ 
• 630407-52-2 6-ethoxy-1,2,3,4-tetrahydro-isoquinoline 
• 252061-94-2 6-benzyloxy-1,2,3,4-tetrahydro-isoquinoline 
• 1340557-66-5 6-propoxy-1,2,3,4-tetrahydroisoquinoline 
• 1623785-70-5 6-hydroxy-2-(3,4,5-trimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064205-77-1 6-hydroxy-2-(3,4,5-trimethoxyphenacetyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064206-28-5 6-hydroxy-2-(3,4,5-trimethoxyphenethyl)-1,2,3,4-tetrahydroisoquinoline 
• 1623785-68-1 2-(3-bromo-4,5-dimethoxybenzyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1064205-97-5 6-hydroxy-2-(3,4,5-triethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides novel compounds having the general formula (I) wherein R1 to R6, and m are as described herein, compositions including the compounds and methods of using the compounds.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS

The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related di

Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors

A structure-activity relationship (SAR) translation strategy was used for the discovery of tetrahydroisoquinoline (THIQ)-based steroidomimetic and chimeric microtubule disruptors based upon a steroidal starting point. A steroid A,B-ring-mimicking THIQ core was connected to methoxyaryl D-ring ring mimics through methylene, carbonyl and sulfonyl linkers to afford a number of steroidomimetic hits (e.g., 7-methoxy-2-(3- methoxybenzyl)-6-sulfamoyloxy-1,2,3, 4-tetrahydroisoquinoline (20 c) GI50=2.1 μM). Optimisation and control experiments demonstrate the complementary SAR of this series and the steroid derivatives that inspired its design. Linkage of the THIQ-based A,B-mimic with the trimethoxyaryl motif prevalent in colchicine site binding microtubule disruptors delivered a series of chimeric molecules whose activity (GI50=40 nM) surpasses that of the parent steroid derivatives. Validation of this strategy was obtained from the excellent oral activity of 7-methoxy-6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4- tetrahydroisoquinoline (20 z) relative to a benchmark steroidal bis- sulfamate Copyright